Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren’t giving them a good review.

Nina King says that Ozempic's rise could shift beauty standards away from thinness as it becomes more accessible.

Lory Osborn says the Wegovy she was prescribed 15 months ago did more than help her lose 75 pounds — over a quarter of her ...

Ozempic is synonymous with weight loss for many people, even as they can turn to drugs with other brand names that have been tailored to treat obesity. The blockbuster Type 2 diabetes medication ...

Drugs like Ozempic could justify a deal. Hershey ‘now faces long-term headwinds from the expansion of GLP-1 drugs and heightened scrutiny on unhealthy food in the U.S.,’ TD Cowen says ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alison Hammond has opened up about her impressive 11-stone weight loss, revealing she achieved it without using Ozempic. The 49-year-old This Morning presenter decided to shed the pounds following ...

People who use Ozempic or Wegovy for weight loss often find they must avoid certain foods to minimize side effects from the medications. Both drugs contain semaglutide, a synthetic version of a ...

Since Ozempic blasted onto the stage in 2017 with ... additional weight loss potential of CagriSema.” Novo Nordisk’s stock fell about 19% in early Friday trading on the news, wiping out ...

It's been one year since I started taking Ozempic and it has changed my life. I was diagnosed with type two diabetes in 2016, following a lifetime of emotional eating. Sugar was my best friend ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

That news was welcome to rival Eli Lilly and Co., which makes weight-loss drugs Zepbound and Mounjaro that compete with Novo Nordisk’s Wegovy and Ozempic. Tomi Kilgore is MarketWatch's deputy ...